loading
Relay Therapeutics Inc stock is traded at $5.84, with a volume of 467.21K. It is up +0.17% in the last 24 hours and down -10.26% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$5.85
Open:
$5.78
24h Volume:
467.21K
Relative Volume:
0.25
Market Cap:
$955.27M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-2.171
EPS:
-2.69
Net Cash Flow:
$-304.44M
1W Performance:
-0.68%
1M Performance:
-10.26%
6M Performance:
-16.76%
1Y Performance:
-22.07%
1-Day Range:
Value
$5.66
$5.92
1-Week Range:
Value
$5.60
$6.09
52-Week Range:
Value
$5.60
$12.14

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name
Name
Relay Therapeutics Inc
Name
Phone
617-370-8837
Name
Address
399 BINNEY STREET, CAMBRIDGE
Name
Employee
304
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
RLAY's Discussions on Twitter

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-20-23 Upgrade Jefferies Underperform → Hold
Apr-19-23 Upgrade Raymond James Outperform → Strong Buy
Apr-13-23 Initiated Raymond James Outperform
Feb-03-23 Initiated Oppenheimer Outperform
Sep-30-22 Initiated Barclays Equal Weight
Sep-02-22 Initiated Stifel Buy
Jun-06-22 Initiated Jefferies Underperform
Feb-01-22 Initiated Berenberg Buy
Jul-21-21 Initiated BofA Securities Buy
Dec-15-20 Reiterated H.C. Wainwright Buy
Dec-08-20 Initiated JMP Securities Mkt Outperform
Nov-05-20 Initiated H.C. Wainwright Buy
Aug-10-20 Initiated Cowen Outperform
Aug-10-20 Initiated Goldman Buy
Aug-10-20 Initiated Guggenheim Buy
Aug-10-20 Initiated JP Morgan Neutral
View All

Relay Therapeutics Inc Stock (RLAY) Latest News

pulisher
Nov 04, 2024

Where are the Opportunities in (RLAY) - Stock Traders Daily

Nov 04, 2024
pulisher
Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024
pulisher
Oct 31, 2024

Relay Therapeutics (RLAY) to Release Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts - Investing.com India

Oct 31, 2024
pulisher
Oct 30, 2024

Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - The Manila Times

Oct 30, 2024
pulisher
Oct 30, 2024

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, - EIN News

Oct 30, 2024
pulisher
Oct 29, 2024

Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy - Barchart

Oct 29, 2024
pulisher
Oct 28, 2024

Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses - Yahoo Finance

Oct 28, 2024
pulisher
Oct 28, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Oct 28, 2024
pulisher
Oct 25, 2024

Several Relay Therapeutics Insiders Sell Shares Sending Potential Negative Signal - Simply Wall St

Oct 25, 2024
pulisher
Oct 25, 2024

Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com Canada

Oct 25, 2024
pulisher
Oct 24, 2024

Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 16, 2024

Financial Snapshot: Analyzing Relay Therapeutics Inc (RLAY)’s Key Ratio Metrics - The Dwinnex

Oct 16, 2024
pulisher
Oct 15, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

How did Relay Therapeutics Inc (RLAY) fare last session? - US Post News

Oct 14, 2024
pulisher
Oct 14, 2024

Relay Therapeutics (NASDAQ:RLAY) Receives Buy Rating from HC Wainwright - MarketBeat

Oct 14, 2024
pulisher
Oct 14, 2024

Relay Therapeutics stock holds price target on FDA approval By Investing.com - Investing.com UK

Oct 14, 2024
pulisher
Oct 14, 2024

Relay Therapeutics Inc (RLAY) receives a Buy rating from Jefferies - Knox Daily

Oct 14, 2024
pulisher
Oct 13, 2024

(RLAY) Trading Report - Stock Traders Daily

Oct 13, 2024
pulisher
Oct 11, 2024

Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat

Oct 11, 2024
pulisher
Oct 10, 2024

Relay Therapeutics Inc: Analyzing RLAY Stock Trends - The InvestChronicle

Oct 10, 2024
pulisher
Oct 10, 2024

Relay Therapeutics Inc [NASDAQ: RLAY] Sees Increase in Stock Value - Knox Daily

Oct 10, 2024
pulisher
Oct 10, 2024

Millennium Management LLC Purchases 921,271 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Relay Therapeutics (NASDAQ:RLAY) Shares Down 4%Here's Why - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Its Stock Has Paid Off Big Time For Relay Therapeutics Inc - SETE News

Oct 09, 2024
pulisher
Oct 08, 2024

Thrivent Financial for Lutherans Purchases New Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

Relay Therapeutics Inc (RLAY) is a good investment, but the stock may be overvalued - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Ratio Analysis: Unpacking Relay Therapeutics Inc (RLAY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 07, 2024
pulisher
Oct 07, 2024

Relay Therapeutics Inc (RLAY) may enjoy gains as insiders got busy in the recent days - Knox Daily

Oct 07, 2024
pulisher
Oct 07, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Dimensional Fund Advisors LP - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

Marshall Wace LLP Purchases New Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

Relay Therapeutics to Lay Off 10% of Workforce - BioSpace

Oct 04, 2024
pulisher
Oct 04, 2024

Relay Therapeutics cuts 10% of staff after positive trial data - The Business Journals

Oct 04, 2024
pulisher
Oct 03, 2024

insider Rahmer Peter sale 245 shares of Relay Therapeutics Inc [RLAY] - Knox Daily

Oct 03, 2024
pulisher
Oct 03, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

Relay Therapeutics executive sells shares worth over $2,200 By Investing.com - Investing.com Australia

Oct 02, 2024
pulisher
Oct 02, 2024

Stocks of Relay Therapeutics Inc (RLAY) are poised to climb above their peers - SETE News

Oct 02, 2024
pulisher
Oct 02, 2024

RLAY’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Oct 02, 2024
pulisher
Oct 02, 2024

Relay Therapeutics executive sells shares worth over $4,800 - Investing.com India

Oct 02, 2024
pulisher
Oct 02, 2024

Biotech layoff tracker: 13 biotechs cut over 1,400 jobs - The Business Journals

Oct 02, 2024
pulisher
Oct 01, 2024

Relay Therapeutics executive sells shares worth over $2,200 - Investing.com

Oct 01, 2024
pulisher
Oct 01, 2024

Relay Therapeutics executive sells shares worth over $4,800 By Investing.com - Investing.com Australia

Oct 01, 2024

Relay Therapeutics Inc Stock (RLAY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Relay Therapeutics Inc Stock (RLAY) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Catinazzo Thomas
Chief Financial Officer
Oct 28 '24
Sale
6.06
6,802
41,220
306,391
Catinazzo Thomas
Chief Financial Officer
Oct 29 '24
Sale
5.95
2,300
13,685
304,091
Bergstrom Donald A
President, R&D
Oct 28 '24
Sale
6.06
2,688
16,289
520,745
Adams Brian
Chief Legal Officer
Oct 28 '24
Sale
6.06
1,632
9,890
321,907
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):